

### NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE


## **Single Technology Appraisal**

# Pitolisant for treating narcolepsy in children and young people 6 to 17 years ID6353

### **Provisional Stakeholder List**

Consultees	Commentators (no right to submit or
	appeal)
Company	<u>General</u>
Bioprojet UK (Pitolisant)	<ul> <li>All Wales Therapeutics and Toxicology Centre</li> </ul>
Patient/carer groups	<ul> <li>Allied Health Professionals Federation</li> </ul>
<ul><li>Narcolepsy UK</li><li>Neurological Alliance</li></ul>	<ul> <li>Board of Community Health Councils in Wales</li> </ul>
South Asian Health Foundation	British National Formulary
Specialised Healthcare Alliance	Care Quality Commission
Ti D : OL :	<ul> <li>Department of Health, Social Services</li> </ul>
	and Public Safety for Northern Ireland
The Sleep Council	
Healthcare professional groups	Healthcare Improvement Scotland     Medicines and Healthcare products
Healthcare professional groups	Medicines and Healthcare products     Pagulatory Agency
Association for Respiratory  Tachnology & Physiology	Regulatory Agency
Technology & Physiology	National Association of Primary Care     National Pharmany Association
Association of British Neurologists	National Pharmacy Association
Association of Respiratory Nurse     Specialists	NHS Confederation
Specialists	Scottish Medicines Consortium
British Association of Neuroscience     Nurses	Welsh Government
Nurses	Welsh Health Specialised Services
British Geriatrics Society  British Neuropoth degree   Society	Committee
British Neuropathological Society	D 11
British Neuropsychiatry Association	Possible comparator companies
British Sleep Society	Aristo Pharma (sodium oxybate)
British Society of Dental Sleep	AS Kaleks (sodium oxybate)
Medicine	Aspire Pharma (atomoxetine)
British Thoracic Society	<ul> <li>Atnahs Pharma UK (solriamfetol)</li> </ul>
Institute of Neurology	<ul> <li>Aurobindo Pharma – Milpharm</li> </ul>
National Heart and Lung Institute	(atomoxetine, modafinil)
Primary Care and Community	<ul> <li>Brown &amp; Burk UK (dexamfetamine)</li> </ul>
Neurology Society	<ul> <li>Dr. Reddy's Laboratories (atomoxetine)</li> </ul>
Primary Care Respiratory Society UK	<ul> <li>Eli Lilly (atomoxetine)</li> </ul>
Royal College of General Practitioners	<ul> <li>Flynn Pharma (methylphenidate)</li> </ul>
Royal College of Nursing	Genus Pharmaceuticals (atomoxetine)
Royal College of Pathologists	Glenmark Pharmaceuticals Europe
Royal College of Physicians	(atomoxetine)
Royal Pharmaceutical Society	Janssen-Cilag (methylphenidate)

Provisional stakeholder list for the evaluation of pitolisant for treating narcolepsy in children and young people 6 to 17 years ID6353



Consultees	Commentators (no right to submit or appeal)
<ul> <li>Royal Society of Medicine – Sleep Specialists</li> <li>UK Clinical Pharmacy Association</li> <li>Others</li> <li>Department of Health and Social Care</li> <li>Guy's and St Thomas' Hospital</li> <li>Imperial College Healthcare Sleep Centre</li> <li>King's College Hospital</li> <li>National Hospital for Neurology and Neurosurgery</li> <li>NHS England</li> <li>Royal Brompton Centre for Sleep</li> <li>The Evelina Children's Hospital</li> </ul>	<ul> <li>Martindale Pharma (methylphenidate)</li> <li>Medice (dexamfetamine, methylphenidate)</li> <li>Mylan (methylphenidate)</li> <li>Neuraxpharm UK (atomoxetine, sodium oxybate)</li> <li>Rosemont Pharmaceuticals (dexamfetamine)</li> <li>Sandoz (atomoxetine, methylphenidate)</li> <li>Sovereign Medical (dexamfetamine)</li> <li>Takeda (lisdexamfetamine, methylphenidate)</li> <li>Teva Pharma (modafinil)</li> <li>UCB Pharma (sodium oxybate)</li> <li>Zentiva (methylphenidate)</li> </ul>
	<ul> <li>Relevant research groups</li> <li>Brain Research UK</li> <li>British Association for Lung Research</li> <li>Cochrane Common Mental Disorders Group         Cochrane UK</li> <li>Genomics England</li> <li>MRC Clinical Trials Unit</li> <li>National Institute for Health Research</li> <li>Associated Public Health groups</li> <li>Public Health Wales</li> <li>UK Health Security Agency</li> </ul>


NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the stakeholder list, and which organisations we should include that have a particular focus on relevant equality issues.

#### **Definitions:**

## <u>Consultees</u>

Organisations that accept an invitation to participate in the evaluation; the company that markets the technology; national professional organisations; national patient organisations; the Department of Health and Social Care and relevant NHS organisations in England.

Provisional stakeholder list for the evaluation of pitolisant for treating narcolepsy in children and young people 6 to 17 years ID6353



The company that markets the technology is invited to make an evidence submission, respond to consultations, nominate clinical experts and has the right to appeal against the Final Draft Guidance (FDG).

All non-company consultees are invited to submit a statement relevant to the group they are representing, respond to consultations, nominate clinical or patient experts and have the right to appeal against the Final Draft Guidance (FDG).

#### Commentators

Organisations that engage in the evaluation process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FDG for information only, without right of appeal. These organisations are: companies that market comparator technologies; Healthcare Improvement Scotland; related research groups where appropriate (for example, the Medical Research Council [MRC]); other groups (for example, the NHS Confederation and the British National Formulary).

All non-company commentators are invited to nominate clinical or patient experts.